Fenofibrate in the Management of Abdominal Aortic Aneurysms

Phase 4

Completed

• Conditions: Abdominal Aortic Aneurysm (AAA); Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12612001226897
• Lead Sponsor: James Cook University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Ability to provide written informed consent
Diagnosis of an asymptomatic abdominal aortic aneurysm which is infrarenal in location and is equal to or greater than 50mm in diameter
Planned elective open repair of infrarenal abdominal aortic aneurysm
High likelihood of medication compliance

Exclusion Criteria

Current use of any fenofibrate or related fibrates
contra-indication to fenofibrate including; liver impairment demonstrated by abnormal liver function tests (greater than or equal to 1.5 times normal upper limit); renal impairment (serum creatinine greater than or equal to 150 micromole); symptomatic gallbladder disease; previous reaction to any lipid modifying medication.
Previous aortic surgery
A Mycotic abdominal aortic aneurysm
A requirement for emergency or urgent open abdominal aortic aneurysm repair
Current enrolment in any other drug trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified